How tirzepatide works — and why the dual mechanism matters

You've heard the word 'dual', here's what that actually means in practice

Picture your digestive system sending two separate signals after a meal. One travels via GLP-1 receptors, telling the brain you're satisfied and slowing the pace at which food leaves the stomach. The other travels via GIP receptors, influencing how fat cells respond to insulin and contributing an additional signal of fullness. Most GLP-1 medicines activate only the first of those two pathways. Tirzepatide (sold in the UK as Mounjaro) activates both at once, and that combination is what makes its mechanism distinct from anything else currently licensed here.

The practical result: appetite falls more consistently across the day, not just in the hour or two after eating. Gastric emptying slows, so meals feel more satisfying from smaller portions. Blood-sugar regulation improves, partly because both receptors influence insulin secretion in a glucose-dependent way, meaning the effect is tied to how much sugar is actually present, which reduces the risk of blood sugar dropping too low in people without diabetes.

It is worth being clear that tirzepatide is not a stimulant and does not speed up metabolism in the way people sometimes expect. The weight change happens because the body's hunger and satiety signals shift. People eat less, not because they are forcing themselves to, but because the biological drive to eat eases. That distinction matters, both for understanding what you are taking and for setting realistic expectations.

For a closer look at what the GIP arm of this mechanism contributes specifically, the role of GIP in tirzepatide's action is explored in more detail.

What happens from the first dose to the maintenance phase

Treatment starts at 2.5 mg. That first pen is not there to produce dramatic results, it exists so that the body can adjust gradually, reducing the chance of nausea or digestive discomfort. The dose is then titrated upward, typically in four-week steps, by the prescriber, based on how you're getting on and your clinical picture. The available UK strengths run from 2.5 mg through to 15 mg.

The question patients most often ask our prescribers at this stage is how long things take to feel different. Appetite changes are usually noticeable within the first few weeks, though the full effect builds over months as the dose increases. How long tirzepatide takes to work depends on the individual and on which dose they reach, it is a gradual process, not an overnight switch.

One thing that sometimes catches people out: if you are starting treatment just before a bank holiday or a family trip abroad, the dosing schedule still runs to the week. Timing doesn't need to be exact, but it is worth building the injection day into a routine that will hold. A Monday order placed before 12 pm, for example, typically arrives Tuesday, but if your usual day falls on a public holiday, talk to your prescriber about the practical steps.

The full physiological picture of what tirzepatide does in the body covers the downstream effects in more detail, including what the evidence shows about fat tissue and metabolic changes over the course of a full treatment course.

What the clinical trial evidence tells us about effectiveness

The evidence base for tirzepatide in weight management is substantial. The SURMOUNT-1 trial (a 72-week study involving thousands of adults with obesity and no diabetes) found that people on the 15 mg dose lost an average of around 20–21% of body weight alongside a reduced-calorie diet and increased physical activity. That result was published in the New England Journal of Medicine and formed part of the evidence base used by NICE when it recommended tirzepatide for NHS use in December 2024.

In the subsequent SURMOUNT-5 trial, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg in a head-to-head comparison over 72 weeks. These are the only two injectable weight-loss medicines currently licensed in the UK, and the comparison is the most direct evidence we have. Results at lower doses of tirzepatide were smaller, which is expected and does not mean lower doses fail; for many people they produce meaningful change alongside fewer gastrointestinal side effects.

It is also worth noting that these figures come from controlled trial conditions with structured lifestyle support. Real-world outcomes vary. The medicine does not work independently of behaviour, it works alongside it, making changes to eating habits considerably more achievable for many people. Whether tirzepatide is appropriate for you depends on your full clinical picture, which is exactly what the prescriber assessment is designed to establish.

For context on what private treatment costs and what is included, the Eli Lilly UK price change and what it means for private patients gives a clear picture. If you want to understand the full range of weight-loss treatment options available, including how tirzepatide compares to semaglutide, our treatment overview covers both.

Side effects and what to watch for

The most common side effects of tirzepatide are gastrointestinal: nausea, loose stools or constipation, burping, indigestion and occasionally vomiting. These are most likely after a dose starts or increases, and they typically settle within days to a couple of weeks as the body adjusts. Fatigue, headache and mild dizziness are also reported. The NHS tirzepatide medicines page lists the full side-effect profile, and the medicine's Patient Information Leaflet remains the definitive reference for anything dose-specific.

A small number of people experience more serious effects. Acute pancreatitis is an infrequent but serious risk: severe stomach pain (particularly pain that spreads to the back and persists) needs prompt medical attention. Gallbladder problems, allergic reactions and, in people with existing diabetic eye conditions, changes in vision can occur. If you experience any of these, contact a healthcare professional promptly rather than waiting for your next check-in.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. Women taking the oral contraceptive pill should discuss additional contraceptive measures with their prescriber for the first four weeks of treatment and for four weeks after each dose increase, since absorption of the pill may be reduced. These are clinical factors that a prescriber weighs up during your assessment.

Our tirzepatide overview covers eligibility in more detail, and our clinical team reviews every consultation personally, if you'd like to explore whether treatment is appropriate for your situation, you can check your eligibility with a free consultation.